Article Contents ::
- 1 The Brand Name EMGARD Has Generic Salt :: Phenobarbitone
- 2 EMGARD Is From Company Medopharm Priced :: Rs. 9
- 3 EMGARD have Phenobarbitone is comes under Sub class #N/A of Main Class #N/A
- 4 Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name EMGARD Has Generic Salt :: Phenobarbitone
EMGARD Is From Company Medopharm Priced :: Rs. 9
EMGARD have Phenobarbitone is comes under Sub class #N/A of Main Class #N/A
Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
|Brand Name||Company / Manufacturers||Strength||Unit||Price / 10|
|EMGARD||Medopharm||30 MG||10||Rs. 9|
|Company Brand Name||Salt Combination||Main Medical Class||Sub Medical Class|
|From Medopharm :: EMGARD||Phenobarbitone||#N/A||#N/A|
Indications for Drugs ::
Status epilepticus, Partial seizures, Sedation, Generalised tonic-clonic seizures, Hypnotic, Preoperative sedation
Drug Dose ::
Adult: PO Generalised tonic-clonic seizures; Partial seizures 60-180 mg/day at night. Adjust according to response. Sedation 30-120 mg/day in 2-3 divided doses. Hypnotic 100-320 mg at bedtime. Pediatric Oral Dosage: Preoperative: 1 mg to 3 mg/kg. Anticonvulsant: 1 mg to 6 mg/kg per day Renal impairment: CrCl (ml/min) <10 Administer every 12-16 hr. Hepatic impairment: Severe: Monitor plasma levels and adjust dose as necessary. Contraindication ::
Severe renal and hepatic disorders. Severe respiratory depression, dyspnoea or airway obstruction; porphyria. Pregnancy.
Drug Precautions ::
Elderly or debilitated patients, children. Withdraw gradually. Impaired renal, hepatic and respiratory function. Patients with acute pain and depressive disorders. May impair ability to drive or operate machinery. Lactation.
Drug Side Effects ::
Bradycardia, hypotension, syncope; drowsiness, lethargy, CNS excitation or depression, impaired judgment, hangover effect, confusion, somnolence, agitation, hyperkinesia, ataxia, nervousness, headache, insomnia, nightmares, hallucinations, anxiety, dizziness; rash, exfoliative dermatitis; nausea, vomiting, constipation; agranulocytosis, thrombocytopenia, megaloblastic anaemia; pain at inj site, thrombophlebitis (IV); oliguria: laryngospasm, respiratory depression, apnoea (especially with rapid IV admin), hypoventilation. Potentially Fatal: Stevens-Johnson syndrome.
Pregnancy category ::
Drug Mode of Action ::
Phenobarbitone is a short-acting barbiturate. It depresses the sensory cortex, reduces motor activity, changes cerebellar function, and produces drowsiness, sedation and hypnosis. Its anticonvulsant property is exhibited at high doses.
Drug Interactions ::
May enhance the hepatotoxic potential of paracetemaol overdoses. May decrease levels/effects of various CYP isoenzyme substrates e.g. teniposide, methotrexate, antipsychotics, ?-blockers, calcium-channel blockers, other anticonvulsants, chloramphenicol, cimetidine, corticosteroids, ciclosporin, doxycycline, oestrogens, felbamate, griseofulvin, tacrolimus, furosemide, methadone, oral contraceptives, theophylline, TCAs, warfarin. May reduce effects of guanfacine. Reduced metabolism and or increased toxicity with chloramphenicol, felbamate, MAOIs, valproic acid. May enhance the nephrotoxic effects of methoxyflurane. Potentially Fatal: Additive sedation and/or respiratory depression with ethanol, sedatives, antidepressants, opioid analgesics, benzodiazepines and other CNS depressants. May decrease levels/effects of antiarrhythmic drugs e.g. disopyramide, propafenone, quinidine.